Clinical Trial Update: TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating induction chemotherapy regimens TPC vs GP, each combined with Nimotuzumab and Toripalimab, for high-risk locally advanced nasopharyngea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: High Risk Locally Advanced Nasopharyngeal Carcinoma | Phase 3 | Status: NOT_YET_RECRUITING